Background: To compare non-coplanar and coplanar volumetric-modulated arc therapy (VMAT) for hippocampal avoidance during whole-brain radiotherapy (HA-WBRT) using the Elekta Synergy and Pinnacle treatment planning system (TPS) according to the suggested criteria of the radiation therapy oncology group (RTOG) 0933 trial.Methods: Nine patients who underwent WBRT were selected for this retrospective study. The hippocampus was contoured, and the hippocampal avoidance regions were created using a 5-mm volumetric expansion around the hippocampus for each patient. Non-coplanar and coplanar VMAT plans were generated for each patient. All treatment plans were generated for a prescribed dose (PD) of 30 Gy in 10 fractions.
Results:The average volumes of the hippocampus and hippocampal avoidance region were 2.8±0.38 and 27±2.48 cm 3 , respectively. For coplanar and non-coplanar VMAT plans, the average D 100% of the hippocampus was 8.60 Gy (range, 8.30-8.80 Gy) and 8.56 Gy (range, 8.30-8.90 Gy), respectively, and the average D max of the hippocampus was 15.29 Gy (range, 14.35-15.92 Gy) and 14.99 Gy (range, 13.80-15.83 Gy), respectively. The non-coplanar VMAT plans showed a significantly lower average D max of the lens (4.23 Gy) than did the coplanar VMAT plans (4.77 Gy). The average gamma passing rate for non-coplanar and coplanar VMAT quality assurance (QA) with criteria of 3%/3 mm were 95.4%±2.6% and 95.6%±1.6%, indicating good agreement between the calculated plan dose and the measured dose.
Conclusions:We showed that the suggested criteria of the RTOG 0933 trial for the hippocampal dose can be achieved in both coplanar and non-planar VMAT plans. We performed VMAT QA for each treatment plan to verify the clinical feasibility.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.